320 results on '"L B Lazebnik"'
Search Results
2. MINERAL METABOLISM AND BONE MINERAL DENSITY IN PATIENTS WITH CENTRAL HYPOGONADISM AS INDICATORS OF PREMATURE AGING
- Author
-
I A Ilovaiskaya, L B Lazebnik, V Yu Zektser, A V Dreval, and G A Melnichenko
- Subjects
минеральный обмен ,минеральная плотность кости ,центральный гипогонадизм у женщин ,гипопитуитаризм ,преждевременное старение ,Osteopathy ,RZ301-397.5 - Abstract
Aim of this study was to estimate the markers of mineral turnover and BMD in young women with the central hypogonadism, to compare them with healthy young women and healthy postmenopausal women of middle/advanced age. Materials and methods. One hundred seventy women were included in the study: 73 patients with the central hypogonadism (isolated hypogonadism n=35, hypopituitarism n=38), age of 25 [21.2; 30.5] y.o., amenorrhea duration 5 [2.3; 10.1] years; 47 healthy women with regular menstrual cycles, age 24 [23.1; 28.0] y.o., and 50 healthy women with natural menopause, age 56 [53; 58] y.o., menopause duration 6.0 [2.1; 10.0] years. Groups did not differ by age. Results. In patients with central female hypogonadism concentrations of calcium and alkaline phosphatase were significantly higher than in healthy women of similar age, however did not differ from the parameters in postmenopausal women. T-scores
- Published
- 2015
- Full Text
- View/download PDF
3. Value of adhesion molecules for evaluating the efficiency of therapy for ulcerative colitis and Crohn's disease
- Author
-
A I Parfenov, O N Boldyreva, I N Ruchkina, O V Kniazev, V É Sagynbaeva, P L Shcherbakov, S G Khomeriki, L B Lazebnik, and A G Konopliannikov
- Subjects
inflammatory bowel diseases ,crohn's disease ,ulcerative colitis ,azathioprine ,glucocorticosteroids ,infliximab ,mesenchymal stromal cells ,p-selectin ,e-selectin ,l-selectin ,and svcam-1 integrin ,Medicine - Abstract
AIM: To define the value of adhesion molecules (sVCAM-1 integrin, P-selectin, E-selectin, and L-selectin) for the prediction and evaluation of the efficiency of treatment in patients with ulcerative colitis (UC) and Crohn's disease/MATERIAL AND METHODS: Twenty-six patients with UC and 14 patients with CD were examined. Of them, 16 patients took infliximab (INF) in a dose of 5 mg/kg of body weight according to the standard scheme; 14 patients received cultured mesenchymal stem stromal cells (MSSCs) in a quantity of 150·108 cells, and 10 had azathioprine (AZA) 2 mg/kg and glucocorticosteroids (GCS) 1 mg/kg of body weight. Enzyme immunoassay was used to determine the serum concentration of the adhesion molecules (L-selectin, E-selectin, P-selectin, and sVCAM-1 integrin) before and 2 months after treatment/RESULTS: The signs of bowel inflammatory disease activity and the elevated levels of adhesion molecules whose synthesis did not occur under normal conditions remained in the patients receiving GCS and AZA. INF treatment caused a decrease in P-selectin, E-selectin, and sVCAM-1 levels to 8.9±1.0, 5.5±1.7, and 9.5±4.4 ng/ml, respectively (p
- Published
- 2014
4. Immune response to biological therapy for inflammatory bowel diseases
- Author
-
O V Kniazev, A I Parfenov, I N Ruchkina, L B Lazebnik, and V É Sagynbaeva
- Subjects
crohn's disease ,infliximab ,mesenchymal stromal cells ,immunosuppressants ,glucocorticosteroids ,tnf-α ,inf-γ ,and il-2 ,il-5 ,il-8 ,il-12 ,il-15 ,ulcerative colitis ,Medicine - Abstract
AIM: To study biological (cell and anticytokine) therapy-induced changes in the levels of proinflammatory cytokines in patients with inflammatory bowel diseases (IBD)/MATERIAL AND METHODS: Forty-four patients with chronic continuous or chronic recurrent IBD were examined. According to the performed therapy, the patients were divided into 3 groups: 1) 16 patients who took infliximab; 2) 14 patients who received combination anti-inflammatory therapy with the cultured mesenchymal stromal cells (MSC) being administered; 3) 14 patients who had standard anti-inflammatory therapy with 5-aminosalycilic acid preparations and glucocorticosteroids. The concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), and interleukins (IL)-2, -5, -8, -12, and -15 were determined in the patients' sera before and 2 months after therapy initiation/RESULTS: The elevation in the serum levels of the proinflammatory cytokines TNF-α, INF-γ, and IL-2, -5, -8, -12, and -15 indicates their implication in the pathogenesis of ulcerative colitis and Crohn's disease. Their levels may evaluate both the activity of an inflammatory process and the efficiency of the therapy. The higher level of these cytokines is accompanied by the enhanced activity of diseases, which may be used to diagnose their activity, to predict the course of IBD, and to perform adequate therapy. The decreased level of the proinflammatory cytokines is indicative of the efficiency of the therapy in patients with IBD/CONCLUSION: By reducing TNF-α levels, infliximab therapy results in a decrease in the concentrations of other proinflammatory cytokines (IL-1, -2, -5, -8), thus lowering the inflammatory activity of IBD. MSC transplantation also reduces the level of most proinflammatory cytokines, thus diminishing the intensity of immunopathological processes, which is shown by positive changes in the clinical picture of the disease.
- Published
- 2013
5. Diagnostic value of serum markers of fibrosis in chronic liver diseases
- Author
-
E V Vinnitskaia, V N Drozdov, Iu M Iunusova, G G Varvanina, N A Shaposhnikova, A V Petrakov, E V Tkachenko, and L B Lazebnik
- Subjects
liver fibrosis ,serum markers of fibrosi ,Medicine - Abstract
AIM: To estimate the diagnostic value (DV) of direct markers of liver fibrosis, such as type IV collagen (C-IV), hyaluronic acid (HA), tissue inhibitor of metalloproteinases-1 (TIMP-1) in combination with indirect markers of fibrosis, such as alanine aminotransferase (АLT), aspartate aminotransferase (AST), and γ-glutamyl transpeptidase (γ-GTP), alkaline phosphatase (ALP), platelets, tumor necrosis factor-α (TNF-α) in evaluating liver fibrosis/MATERIAL AND METHODS: Sixty-seven patients with chronic diffuse liver diseases were examined. ALT, AST, γ-GTP, and ALP were determined as indirect indicators of fibrosis. The levels of TIMP-1, HA, C-IV, and TNF-α were estimated by ELISA; the stage of fibrosis was determined by the results of indirect liver ultrasound fibroelastography (FE)/RESULTS: According to the results of FE, the patients were divided into 2 groups: 1) (n=25) F≤2 METAVIR and 2) (n=42) F3-F4. While estimating DV of severe fibrosis stages (F3-F4), the area under the ROC curve (AUC) increased for platelets, HA, and C-IV. DV of ALT, AST declined with the higher degree of fibrosis. The highest ratio of test specificity and sensitivity (TSp and TSen) and AUC were observed for AST and HA. ALT and platelets showed low TSen, and TNF-α and TIMP-1 had no TSp. For evaluation of fibrosis (F4), a HA increase of over 57.7 ng/ml had 92.6% TSen and 67.5% TSp; for a C-IV elevation of above 133.1mkg/l, TSen was 85.2%, TSp was 57.5%; for a TIMP-1 rise from 24.4 ng/ml, TSen was 74.1% and TSp was 62.5%. For the diagnosis of fibrosis (F4) with a HA rise of more than 57.7 ng/ml, DV of a positive test was 65.8 (48.65-80.4; 95% CI) and that of a negative test was 93.1 (76.8-99.2; 95% CI). Thus, the negative rather than positive test results are of great diagnostic value for evaluation of the degree of fibrosis/CONCLUSION: The results of the investigation convincingly suggest that examination of the serum markers of fibrosis allows one to estimate with a high probability its presence and severity in patients with hepatic cirrhosis. The so-called direct markers (substances reflecting the biochemistry and regulation of fibrogenesis) are undoubtedly of great diagnostic value.
- Published
- 2013
6. Complete elimination of cytomegalovirus without antiviral therapy after systemic mesenchymal stromal cell transplantation in a patient with ulcerative colitis (a clinical case)
- Author
-
O V Kniazev, L B Lazebnik, A I Parfenov, I N Ruchkina, P L Shcherbakov, A G Konopliannikov, Z F Mikhaĭlova, and S G Khomeriki
- Subjects
cytomegalovirus infection ,ulcerative colitis ,Medicine - Abstract
Cytomegalovirus (CMV) is one of the common pathogens of opportunistic infections in patients with inflammatory bowel diseases. When the patients are treated with immunosuppressants that make them more susceptible to CMV, the course of ulcerative colitis (UC) becomes considerably worse. Antiviral therapy sometimes can reduce the risk of complications and the rate of colectomies. At the same time, antiviral therapy is not mandatory for all UC patients with CMV infection, as shown by the results of numerous investigations. One of the properties of mesenchymal stromal cells (MSC) is to suppress the body's immune reactions to allostimulation, rather than to infection invasion. In vivo and in vitro studies have demonstrated that MSCs have antiviral and antimicrobial activities. The described clinical case shows that clinical improvement occurred and a drastic activation of proliferative processes in the colonic mucosa was detected in the patient with UC after MSC transplantation. Administration of cultured MSCs also promoted the elimination of CMV without antiviral therapy and the overcoming of hormone dependence/resistance in the patient with UC.
- Published
- 2012
7. Optimization of cell therapy in patients with inflammatory bowel diseases
- Author
-
L B Lazebnik, O V Kniazev, A I Parfenov, I N Ruchkina, P L Shcherbakov, S G Khomeriki, and A G Konopliannikov
- Subjects
biological therapy ,inflammatory bowel diseases ,mesenchymal stromal cells ,Medicine - Abstract
Aim. To elaborate optimal cell culture administration regimens to enhance the efficiency of anti-inflammatory therapy for inflammatory bowel diseases. Subjects and methods. Three groups of patients with chronic continuous or chronic recurrent ulcerative colitis (UC) were formed according to the treatment option: 1) 15 patients with UC, in whom mesenchymal stromal cells (MSC) were thrice administered for a month at a one-week interval; 2) 20 patients with UC who received MSC once; 3) 20 patients with UC who had standard anti-inflammatory therapy with 5-aminosalycilic acid (5-ASA) preparations and glucocorticosteroids (GCS). The clinical activity of UC was evaluated using the Rachmilewitz index; its endoscopic pattern was assessed with the Mayo index. UC histological specimens were scored using the Gebs scale. To ascertain the duration of remission, the authors used the Kaplan-Maier survival curve method and calculated relative risk (RR) and odds ratio with 95% confidence intervals.Results. Following 12 months, allogeneic bone marrow (BM) MSC transplantation performed thrice during a month caused the greatest reduction in the Rachmilewitz clinical activity index, Mayo endoscopic activity index, and Gebs pathohistological index in patients with UC as compared to those who had underwent one transplantation or received 5-ASA preparations and GCS (p
- Published
- 2012
8. Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors
- Author
-
Leonid Borisovich Lazebnik, Dmitriy Stanislavovich Bordin, Antonina Aleksandrovna Masharova, Lyudmila Dmitrievna Firsova, Svetlana Yur'evna Sil'vestrova, L B Lazebnik, D S Bordin, A A Masharova, L D Firsova, and S Yu Silvestrova
- Subjects
gastroesophageal reflux disease ,quality of life ,mental status ,ppis pharmacokinetics ,Medicine - Abstract
Aim. The aim of the study was to determine causes of proton pump inhibitors (PPIs) inefficacy in some patients suffering from gastroesophageal reflux disease (GERD). Material and methods. In our study of 154 GERD patients, 50 received omeprazole, 51 - lansoprazole and 53 - pantoprazole in a standard daily dose. GERD symptoms (heartburn and regurgitation) were scored by Likert scale; the patients' quality of life (SF-36) and their mental status (SMALL) were examined. Upper gastrointestinal endoscopy, 24-h intraesophageal pH monitoring, esophageal manometry and pharmacokinetic study were performed. Results. The treatment with a standard dose of PPIs was ineffective in 21 (13.6%) patients. Causes of PPIs inefficacy in 4.5% patients were rapid PPI metabolism and in 9.1% - "driving gear" of symptoms formation related with psychic dysadaptation.
- Published
- 2012
9. Spontaneous bacterial peritonitis and systemic inflammatory reaction in hepatic cirrhosis patients
- Author
-
Elena Vladimirovna Vinnitskaya, Leonid Borisovich Lazebnik, Georgiy Andreevich Osipov, Vladimir Nikolaevich Drozdov, E V Vinnitskaya, L B Lazebnik, G A Osipov, and V N Drozdov
- Subjects
hepatic cirrhosis ,spontaneous bacterial peritonitis ,systemic inflammatory reaction ,Medicine - Abstract
Aim. To develop criteria of early diagnosis of spontaneous bacterial peritonitis (SBP) in hepatic cirrhosis (HC). Material and methods. Clinical symptoms of SBP including systemic inflammatory reaction were analysed in 286 patients. The count of polymorphonuclear neutrophils (PNL) in ascitic liquid (AL), microbiological study of the blood and AL were made. Ultrasound investigation assessed acoustic homogeneity of AL. Blood serum (BS) and AL were tested for cytokines content: interleukine-1beta, TNF-alpha, interleukine-4, transforming growth factor beta, C-reactive protein. Gas chromatography - mass spectrometry (GC-MC) estimated quantity and quality of chemical components - markers of potential infectious agents of AL. Results. Three groups of patients were identified: group A (a classic SBP) consisted of 23 patients with clinical symptoms of SBP and PNL content > 0.25109/l; group B (control) consisted of 19 patients free of SBP symptoms and PNL content < 0.25109/l; group C (patients at risk) - 18 patients with SBP symptoms and PNL content < 0.25109/l. Cultural test of AL was negative in all the groups. Symptoms of SIR occurred equally often in groups A and C. CRP in AL was higher (23.8±4.3 g/l) in group A than in group B (p < 0.05). CRP concentration (8.6±2.1 g/l) was higher in group C than in group B (p < 0.05). Changes in cytokine composition were similar in groups A and C. The number of chemical bacterial markers was higher in groups A and C (p < 0.005). Conclusion. Patients of group C with SIR, elevated CRP, changed cytokine status, high content of chemical markers of AL infection by GC-MC are at high risk of SBP. Such patients need adequate and early antibacterial therapy.
- Published
- 2011
10. The role of immune system in development of structural changes in colonic mucosa in diverticulosis
- Author
-
Svetlana Vladimirovna Levchenko, Raisa Borisovna Gudkova, Valentina Borisovna Potapova, Asfol'd Ivanovich Parfenov, Vera Aleksandrovna Rogozina, Leonid Borisovich Lazebnik, S V Levchenko, R B Gudkova, V B Potapova, A I Parfenov, V A Rogozina, and L B Lazebnik
- Subjects
diverticulosis ,antibodies to tissue proteins ,antiglycanic antibodies ,immunocompetent cells ,epithelial proliferation ,Medicine - Abstract
Aim. To determine the role of immune response with production of auto- and heterologous antibodies (Ab) in development of the pathological process and in structural changes in colon mucosa (CM) in diverticulosis (Dv). Material and methods. Of 219 Dv patients, 39 were newly diagnosed with x-ray-detected signs of previous inflammation (group 1), 180 had earlier detected Dv which was confirmed and endoscopic examination detected inflammation (group 2). The comparison group consisted of 25 patients with irritable colon syndrome. The immune status was assessed by concentration of immunoglobulins (Ig), auto- and heterologous Ab. Antibodies to catalytic cytoplasmic antigens to proteinase-3, myeloperoxidase, bactericide protein BPI, tissue transglutaminase (tTG) and antiglycanic Ab were detected with solid-phase enzyme immunoassay. Results. IgA and IgG levels in group 2 were significantly higher than in group 1 and in the controls. Elevation of both IgA and IgG levels reflects activation of B-cell immunity. Group 2 patients had a higher level of Ab to endogenic peptides Saccharomyces cerevisiae (ASCA) of class IgG and IgA than group 1 and controls. The level of Ab to tissue molecules was elevated: antibodies to tTG IgG were detected in both groups - in group 2 twice more often than in group 1, while Ab to BPI - in 27% cases in group 1 and in 97% - in group 2. IgG Ab to antigens associated with phagocytic cells were detected in group 2, while Ab in group 1 were positive in single cases. Conclusion. Activation of immune response with a high concentration of IgA and IgG, Ab to tissue antigens (BPI, tTG) and IgGAb to catalytic antigens is characteristic of chronic course of Dv. Morphological changes in CM reflect different severity of inflammation-dystrophic process.
- Published
- 2011
11. Biological treatment of gastrointestinal diseases
- Author
-
Leonid Borisovich Lazebnik and L B Lazebnik
- Subjects
crohn's disease ,hepatic cirrhosis ,anticytokine therapy ,infliximab ,transplantation of mesenchymal stromal cells ,Medicine - Abstract
Biological methods are widely used in the treatment of intestinal inflammation (II). The TNFalpha inhibitor infliximab can quickly correct recurrence, provide long-term remission and reduce hormone need in many patients with hormone-resistant and hormone-dependent forms of Crohn's disease (CD) and ulcerative colitis (UC). However, almost half of II patients fail anticytokine therapy. Some clinical trials of biological medicines were stopped because of toxicity and complications. One of promising approaches to II treatment is now transplantation of mesenchymal stromal cells (MSC). The trial with participation of 85 CD and UC patients demonstrates that intravenous injection of allogenic MSC significantly prolongs duration of remission, reduces recurrence risk and is indicated for patients with hormone-resistent, hormone-dependent forms of II. Cell therapy can be also used in combined treatment of other gastrointestinal diseases, hepatic cirrhosis, in particular. A clinical trial is initiated of efficacy of transplantation of bone marrow autologous cells CD133+ for stimulation of regeneration of the liver in its extensive resection and cirrhosis. The future of this method depends on the results of controlled, randomized clinical trials.
- Published
- 2011
12. Results of a multicenter trial 'Epidemiology of Gastroesophageal Reflux Disease in Russia' (MEGRE)
- Author
-
Leonid Borisovich Lazebnik, Antonina Aleksandrovna Masharova, Dmitriy Stanislavovich Bordin, Yuriy Vasil'evich Vasil'ev, Evgeniy Ivanovich Tkachenko, Rustem Abbasovich Abdulkhakov, Mikhail Aleksandrovich Butov, Elena Yur'evna Eremina, Lyudmila Ivanovna Zinchuk, Vladislav Vladimirovich Tsukanov, L B Lazebnik, A A Masharova, D S Bordin, Yu V Vasiliev, E I Tkachenko, R A Abdulkhakov, M A Butov, E Yu Eremina, L I Zinchuk, and V V Tsukanov
- Subjects
epidemiology ,gastroesophageal reflux disease ,heartburn ,Medicine - Abstract
Aim. To assess prevalence of gastroesophageal reflux disease (GERD) in Russia in MEGRE trial in 6 cities of the Russian Federatiion (Kazan, Kemerovo, Krasnoyarsk, Ryazan, St-Petersburg, Saransk). Material and methods. Mayo Clinic questionnaire (USA) adapted for Russia was used to question 7812 people over 18 years of age from of random population sample. The symptoms (heartburn and regurgitation) were classified as frequent if they arose once a week and more often for the last 12 months, rare symptoms arose less often than once a week. The responders with frequent heartburn and/or regurgitation were regarded as persons with epidemiological quantitative criteria of GERD. Results. Heartburn occurred in 47.5% responders: frequent in 9%, rare in 38.5%. Regurgitation occurred in 42.9%: frequent in 7.6%, rare in 35.3%. GERD prevalence was 13.3% (city range 11.3-14.3%). Frequent GERD symptoms are associated with frequent gaseous eructation (24.3%), chronic cough (22.9%), chest pain (15.1%), dysphonia (11.4%.). To stop heartburn, 88% responders took antacids, 32% - blockers of histamine H2-receptors and only 23% - inhibitors of proton pump. Only 52.8% responders with frequent chest pain and 29.3% those with frequent hearburn visited a doctor. Conclusion. The population-based trial MEGRE conducted by international methodology in 6 cities of Russia demonstrated that GERD prevalence is 13.3%. Most of the patients pay little attention to the symptoms, do not seek medical advice and, therefore, receive no adequate treatment.
- Published
- 2011
13. Bronchopulmonary lesions in chronic inflammatory bowel diseases
- Author
-
Zyfa Fyaskhetdinovna Mikhaylova, Leonid Borisovich Lazebnik, Asfol'd Ivanovich Parfenov, Z F Mikhailova, L B Lazebnik, and A I Parfenov
- Subjects
review ,inflammatory bowel disease ,lung function ,infliximab ,treatment ,Medicine - Abstract
The paper reviews the literature on bronchopulmonary lesion, one of the least studied systemic manifestations associated with inflammatory bowel diseases (IBD). Knowledge of the entire diversity of extraintestinal manifestations of IBD, including respiratory diseases, allows clinicians to optimize their diagnosis and treatment as the asymptomatic course of the latter may lead to the development of severe respiratory complications. The detection of bronchopulmonary pathology in its early period or during current therapy contributes to the objective assessment of the pattern of the disease, to the correction of treatment and improvement of disease prognosis.
- Published
- 2010
14. USE of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases
- Author
-
Leonid Borisovich Lazebnik, Anatoliy Georgievich Konoplyannikov, Oleg Vladimirovich Knyazev, Asfol'd Ivanovich Parfenov, Tamara Mikhaylovna Tsaregorodtseva, Irina Nikolaevna Ruchkina, Sergey Germanovich Khomeriki, Vera Aleksandrovna Rogozina, Ol'ga Andreevna Konoplyannikova, L B Lazebnik, A G Konoplyannikov, O V Knyazev, A I Parfenov, T M Tsaregorodtseva, I N Ruchkina, S G Khomeriki, V A Rogozina, and O A Konoplyannikova
- Subjects
allogeneic mesenchymal stem cells ,crohn's disease ,ulcerative colitis ,Medicine - Abstract
Aim. to determine the whether mesenchymal stem cells (MSC) may be used in the treatment of patients with chronic intestinal inflammatory diseases (IID). Subjects and methods. Thirty-nine patients with ulcerative colitis (UC) (Group 1) and 11 with Crohn's disease (CD) (Group 2) were examined. Comparative groups included 30 patients with UC (Group 2) and 10 with CD (Group 4). Two-three days before MSC administration, immunodepressants were discontinued, the dosage of corticosteroids was reduced to 15-20 mg/day, and that of aminosalicylates remained to be 2 g/day. The results were quantified using the mean values of the Rachmilewich clinical activity index, the Crohn's disease activity index and the Mayo and Gebs scales. The patients were followed up for 4-8 months. Humoral immunological indices (cytokines, autologous antibodies) were determined. Bone marrow cells were obtained from the donor sternum or iliac crest. Cultivation at the end of weeks 5-6 provided a population of allogeneic donor MSC in a quantity of (1.5-2)108 cells required for transplantation to a patient. MSC cultures were once injected intravenously in a dropwise fashion. Results. A statistically significant decrease in the indices of the clinical and morphological activities of an inflammatory process was noted in 39 patients with UC and in 11 patients with CD as compared with the comparison groups after MSC transplantation. Clinicomorphological remission occurred in 40 patients. Inclusion of MSC into the treatment program was ineffective in 8 patients with UC and in 2 patients with CD. The use of MSC made it possible to discontinue corticosteroids in 34 of the 50 patients with the hormone-dependent and hormone-resistant forms of UC and CD and to reduce the dose of prednisolone to 5 mg/day in 7 patients, by administering 5-aminosalicylic acid only. Conclusion. The use of MSC may be appreciated as a new strategic direction of therapy for IID. The intravenously administered stem cells exert a potent immunomodulatory effect, reduce the activity of autoimmune inflammation, and stimulate a reparative process in the intestinal mucosa.
- Published
- 2010
15. Spontaneous bacterial peritonitis: pathogenesis problems
- Author
-
Leonid Borisovich Lazebnik, E V Vinnitskaya, and L B Lazebnik
- Subjects
review ,cirrhosis of the liver ,spontaneous bacterial peritonitis ,bacterial translocation ,excessive bacterial growth ,pathogenesis ,systemic inflammatory reaction ,Medicine - Published
- 2009
16. H. pylori in development of allergic diseases in patients with gastroduodenal diseases
- Author
-
L B Lazebnik, S P Chernutskaya, V B Gervazieva, and G V Sukhareva
- Subjects
h. pylori ,igg-at ,ige ,h.pylori ,igg-ab ,iga-ab to h.pylori ,allergy ,Medicine - Abstract
Aim. To discover relations between allergic diseases and H.pylori infection in patients with gastroduodenal diseases. Material and methods. The study was made of 113 patients (age 22-65, 34 males and 79 females) with chronic gastritis and duodenal ulcer. Of them, 60 patients (group 1) had concomitant allergy (urticaria, bronchial asthma, atopic dermatitis, food allergy, pollinosis), while 53 patients (group 2) had no allergy. H.pylori infection was diagnosed with the respiratory and rapid urease test, histological and cytological tests. Enzyme immunoassay determined total antibodies (AB) to H.pylori in IgG, IgA, IgM classes; IgA-AB in the kits Vector Best (Russia), IgG-AB to H.pylori in the kits of ECOLab (Russia) and total IgE in the kits IgE-EIA (Stavropol). Results. In group 1 total AB to H.pylori were positive in 48 (80%), IgG-AB and IgA-AB to H.pylori in 38(63.3%) and 43 (71.6%) patients, respectively. In elevated concentration of AgG-AB to H.pylori 46 (76.6%) patients had elevated total IgE (mean 364 IU.l). In group 2 total AB to H.pylori were detected in 45 (85.0%) patients, IgG-AB and IgA-AB to H.pylori in 47 (88.6%) and 32 (60. 3%), respectively. Among patients with high level of IgG-AB to H.pylori in the serum high total IgE was only in 35.8% patients. Mean IgE was 250 IU/l. Conclusion. Patients with gastroduodenal diseases associated with H.pylori and allergy and not associated had similar level of total AB to H.pylori, while higher total IgE and specific IgE-AT to H.pylori occurred in the former. Thus, H. pylori infection is associated with allergic (atopic) immune response.
- Published
- 2008
17. Epigastric burning and gastroesophageal reflux disease: problems and solutions
- Author
-
L B Lazebnik
- Subjects
editorial ,burning ,gastroesophageal reflux diseas ,Medicine - Published
- 2008
18. Cytokines and cytokine therapy in gastrointestinal diseases
- Author
-
Т М Tsaregorodtseva, Т I Serova, L Yu Ilchenko, G V Sukhareva, G N Sokolova, I E Trubitsyna, K A Nikolskaya, M V Klishina, and L B Lazebnik
- Subjects
cytokines ,cytokine status ,interleukins ,chronic recurrent and chronic progressive gastrointestinal diseases ,cytokine therapy ,Medicine - Abstract
Aim. To compare cytokine status in gastrointestinal diseases (GID) with reference to etiological factor, course, stage, therapy of the disease. Material and methods. Enzyme immunoassay was used to examine cytokines in the peripheral blood, tissue homogenates of 560 GID patients. GID were represented by ulcer disease (UD), cholelithiasis, chronic hepatitis (CH), glutenic enteropathy (GE), Crohn's disease (CD), nonspecific ulcer colitis (NUC). Results. In chronic recurrent GID (UD, cholelithiasis, GE) early exacerbation was characterized by elevated concentrations of IL-ip, IL-6, IL-8. Concentrations of IL-12, Infa,g, TNFa reached maximum on the height of the disease. Intensification of regenerative processes raised concentrations of IL4, IL-10. An overall level of serum cytokines averaged 190-780 pg/ml, reaching in some patients with active disease 1200-3000 pg/ml, in remission 30-110 pg/ml, in the control 40 pg/ml. In chronic progressive GID the levels of IL-10, IL-2, IL-8, IL-6 reached 30-80 pg/ml, IL-12, Infy, TNFa 150-370 pg/ml. A rise in cytokines concentrations in inflammatory viral, bacterial, autoimmune GID was higher than in cancer, alcoholism-related diseases, metabolic disturbances. Basic therapy in patients with chronic recurrent GID led to a significant fall in concentration of serum cytokines. Therapy with monoclonal antibodies to TNFa was associated with transitory pronounced favourable changes in peripheral blood cytokine status. Conclusion. GID provoke elevation of serum and tissue cytokines, impairment of cytokine balance in correlation with the etiological factor, variants of the course, stage of the disease, on-going therapy.
- Published
- 2004
19. Prevalence of gastroesophageal reflux disease in moscow: results of a population study
- Author
-
L B Lazebnik, Iu V Vasil'ev, A A Masharova, and I V Manannikov
- Subjects
gastroesophageal reflux disease ,epidemiology ,epidemiological survey ,detectability ,prevalenc ,Medicine - Abstract
Aim. To study prevalence of the principal symptoms of gastroesophageal reflux disease (GERD) in Moscow. Material and methods. A total of 1065 respondents aged 15-85 years (a random representative sample of population of one of the typical Moscow districts) participated in a questionnaire survey using the international questionnaire for detection of GERD incidence. Results. Epigastric burning (EB) occurs in 39.6% examinees. GERD prevalence is 14.2%. Subjects with EB have the following symptoms of GERD: regurgitation (66.3%), epigastric pain (discomfort) (53.0%), nausea (43.6%), vomiting (23.2%), dysphagia (20.6%), chest pain (18.0%), odinophagia (5.5%), singultus (4.6%). There is a direct correlation between incidence rate of EB, height, body mass index, number of alcohol excesses and smoked sigarettes. Conclusion. EB occurs in both young and aged men and women with similar frequency. Significant differences were detected only in the age group 45-59 years in which EB is more frequent in women. All the symptoms excluding cough and singultus were seen in women significantly more frequently. With age, these differences disappeared but noncardial pain in the chest that was less frequent in the elderly. Muscovites with GERD symptoms are older (61.26 ± 13.47 years) than those without such symptoms (58.44 ± 16.28, p < 0.0001).
- Published
- 2008
20. The role of ferritin in liver disease assessment
- Author
-
V. G. Radchenko, V. B. Grinevich, E. S. Ivanyuk, and L. B. Lazebnik
- Subjects
nonalcoholic fatty liver disease ,nafld ,ferritin ,iron metabolism disorder ,systemic inflammation ,insulin resistance ,human placenta hydrolysate peptides ,laennec ,Therapeutics. Pharmacology ,RM1-950 ,Economics as a science ,HB71-74 - Abstract
Background. Ferritin is an important integral and diagnostic marker of liver diseases. In 1/3 of patients with nonalcoholic fatty liver disease (NAFLD), manifestations of hyperferritinemia are revealed. Increased ferritin level indicates the severity of the disease course and affects the prognosis.Objective: to determine the prevalence and character of hyperferritinemia manifestations in NAFLD patients and to evaluate the effectiveness of its correction with human placenta hydrolysate.Material and methods. We examined 158 patients aged from 20 to 63 years (92 men and 66 women). There were no significant differences in age between men and women. The control group consisted of 20 practically healthy individuals. Molecular mechanisms of peptide components of human placenta hydrolysate (Laennec®) impact on pathophysiological processes of serum ferritin disorders, iron metabolism indicators, and inflammation manifestations were analyzed.Results. Nineteen peptides potentially important for regulation of iron homeostasis were identified in Laennec® composition. These peptides contribute to the elimination of iron metabolism disorders by regulating the levels of hepcidin (the main hormone of iron homeostasis), reducing ferritin synthesis, as well as exhibiting anti-inflammatory, and immunomodulatory effects. The efficacy of the drug monotherapy in patients with hyperferritinemia was shown.Conclusion. Laennec® was found to be one of the medicines contributing to the reduction of hyperferritinemia manifestations, iron metabolism disorders, and systemic inflammatory process in NAFLD.
- Published
- 2023
- Full Text
- View/download PDF
21. 75 years of Konstantin Aleksandrovich Shemerovsky
- Author
-
L. B. Lazebnik
- Subjects
Hepatology ,Gastroenterology - Published
- 2023
- Full Text
- View/download PDF
22. Clostridioides difficile infection: diagnosis, treatment, and prevention Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North- West Society of Gastroenterologists and Hepatologists
- Author
-
O. M. Drapkina, L. B. Lazebnik, I. G. Bakulin, M. S. Zhuravleva, N. V. Bakulina, E. V. Skazyvaeva, S. I. Sitkin, M. I. Skalinskaya, O. I. Solovyeva, E. Yu. Eremina, S. V. Tikhonov, T. S. Fil', T. L. Pilat, Yu. G. Kuznetsova, R. A. Khanferyan, M. A. Livzan, M. F. Osipenko, D. I. Abdulganieva, L. V. Tarasova, and A. I. Khavkin
- Subjects
Hepatology ,Gastroenterology - Abstract
Clostridioides difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea, and an important cause of nosocomial infection. Since the publication of the National Guidelines (2016, 2017), new data have been accumulated on the genetic structure and pathogenic properties of the most common causative agent of severe forms of antibiotic- associated diarrhea, which has led to the reclassifi cation of the pathogen, formerly known as Clostridium diffi cile, to Clostridioides difficile. Laboratory algorithms have been developed to diagnose CDI and determine the toxigenicity of strains reliably. New data on the effectiveness of antibacterials have been published, monoclonal antibodies to toxin B (bezlotoxumab) have been introduced into clinical practice to prevent CDI recurrence, and fecal microbiota transplantation has been proposed. Over the past 5 years, many international guidelines on the management of adult patients with CDI have also been updated (USA, EU). In the last decade, including due to the COVID-19 pandemic, there has been an increase in CDI incidence. Considering therelevance of CDI, new data on the pathogen, and domestic features, the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North-West Society of Gastroenterologists and Hepatologists developed these clinical guidelines.
- Published
- 2023
- Full Text
- View/download PDF
23. Colonic diverticular disease: clinical presentation, diagnosis, treatment, and prevention Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North- West Society of Gastroenterologists and Hepatologists
- Author
-
O. M. Drapkina, L. B. Lazebnik, I. G. Bakulin, E. V. Skazyvaeva, N. V. Bakulina, S. I. Sitkin, M. I. Skalinskaya, M. S. Zhuravleva, E. B. Avalueva, M. A. Livzan, D. S. Bordin, and A. I. Khavkin
- Subjects
Hepatology ,Gastroenterology - Abstract
Clinical guidelines are intended for gastroenterologists, internists, and general practitioners and focus primarily on the management of patients with symptomatic uncomplicated diverticular disease, as well as on the primary and secondary prevention of acute diverticulitis and other complications of diverticular disease. Clinical guidelines were developed by the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientifi c Society of Russia, and the North-West Society of Gastroenterologists and Hepatologists. One of the reasons for creating new clinical guidelines is that the current guidelines on diverticular disease (2021) pay much more attention to complications of diverticular disease and surgical treatment of acute and chronic complications of the disease.
- Published
- 2023
- Full Text
- View/download PDF
24. Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines
- Author
-
V. B. Grinevich, L. B. Lazebnik, Yu. A. Kravchuk, V. G. Radchenko, E. I. Tkachenko, A. M. Pershko, P. V. Seliverstov, C. P. Salikova, K. V. Zhdanov, K. V. Kozlov, V. V. Makienko, I. V. Potapova, E. S. Ivanyuk, D. V. Egorov, E. I. Sas, M. D. Korzheva, N. M. Kozlova, A. K. Ratnikova, V. A. Ratnikov, S. I. Sitkin, L. Z. Bolieva, C. V. Turkina, D. I. Abdulganieva, T. V. Ermolova, S. A. Kozhevnikova, L. V. Tarasova, R. G. Myazin, N. M. Khomeriki, T. L. Pilat, L. P. Kuzmina, R. A. Khanferyan, V. P. Novikova, A. V. Polunina, and A. I. Khavkin
- Subjects
Hepatology ,Gastroenterology - Abstract
Summary Post- COVID syndrome refers to the long-term consequences of a new coronavirus infection COVID-19, which includes a set of symptoms that develop or persist after COVID-19. Symptoms of gastrointestinal disorders in post- COVID syndrome, due to chronic infl ammation, the consequences of organ damage, prolonged hospitalization, social isolation, and other causes, can be persistent and require a multidisciplinary approach. The presented clinical practice guidelines consider the main preventive and therapeutic and diagnostic approaches to the management of patients with gastroenterological manifestations of postCOVID syndrome. The Guidelines were approved by the 17th National Congress of Internal Medicine and the 25th Congress of Gastroenterological Scientifi c Society of Russia.
- Published
- 2023
- Full Text
- View/download PDF
25. Connective tissue and microbiota. The facets of interaction in norm and pathology
- Author
-
E. I. Tkachenko and L. B. Lazebnik
- Subjects
Hepatology ,Gastroenterology - Abstract
The authors consider diseases of internal organs as a reflection of the influence of various factors on the human exposome (as a complex symbiotic system) in the process of formation of the noosphere from the biosphere. At the same time, various exposome factors caused deep violations of the evolutionarily developed symbiotic relationships of a person with the environment and the internal environment with a violation of the basic systems of regulation and adaptation with the development of metabolic imbalance and the subsequent formation of various diseases. The important role of connective tissue in these processes, its various elements in the regulation of the structure of organs and cells, the near-cellular space, metabolism, immunity, ways of interaction with the microbiota and its network structures, decentralized forms of homeostasis regulation are considered.
- Published
- 2023
- Full Text
- View/download PDF
26. Results of a multicenter prospective observational study 'Clinical significance of hyperammonemia in patients with post-Covid syndrome (LIRA - COVID)': efficacy of L-ornithine L-aspartate
- Author
-
L. B. Lazebnik, S. V. Turkina, R. G. Myazin, L. V. Tarasova, T. V. Ermolova, S. A. Kozhevnikova, and D. I. Abdulganieva
- Subjects
Hepatology ,Gastroenterology - Published
- 2023
- Full Text
- View/download PDF
27. Report on the work of the 25th Congress and events of the Gastroenterological Scientifi c Society of Russia (GSSR) for 2022
- Author
-
L. B. Lazebnik
- Subjects
Hepatology ,Gastroenterology - Published
- 2023
- Full Text
- View/download PDF
28. Features of diet therapy for Clostridium difficile- associated disease
- Author
-
T. L. Pilat, L. B. Lazebnik, Y. G. Kuznetzova, and R. A. Khanferyan
- Subjects
Hepatology ,Gastroenterology - Abstract
This review presents literature data on the prevalence, clinical picture, risk factors of development and modern approaches to diet therapy of the disease caused by Clostridium difficile (С. difficile). Particular attention is paid to modern methods of medical nutrition, taking into account the symptoms and factors of intoxication of the organism. Data on the possibility of using domestic products of dietary nutrition treatment for the restoration of the functions of the organism, the state of the microbiome, the detoxification of the organism and its rehydration have been analyzed.
- Published
- 2022
- Full Text
- View/download PDF
29. Chemomicrobiome analysis of lithium ascorbate and other organic lithium salts
- Author
-
I. Yu. Torshin, O. A. Gromova, and L. B. Lazebnik
- Subjects
Hepatology ,Gastroenterology - Abstract
Lithium salts are used in medicine as normotimics. An important aspect of the action of any medicine, incl. lithium salts is their effect on the human microbiota (microbiome). This work presents the results of a comparative chemomicrobiome analysis of organic lithium salts: ascorbate, comenate, nicotinate, oxybutyrate, aspartate and lithium orotate, carried out using modern technologies for the analysis of “big data”. For each of the studied lithium salts, estimates of the values of the area under the growth curve (AUC) were obtained for a representative sample of human microbiota, which included 38 commensal bacteria (including various species of bifidobacteria and lactobacilli) and the values of the minimum inhibitory concentrations (MIC) for 120 pathogenic bacteria. On average, over a representative sample of microbiota, lithium ascorbate supported the growth of all commensal bacteria to a somewhat greater extent (AUC = 0.57 ± 0.15) than comenat (AUC = 0.47 ± 0.17), nicotinate (AUC = 0.45 ± 0.22), lithium oxybutyrate (AUC = 0.22 ± 0.17), lithium aspartate (AUC = 0.31 ± 0.14) and lithium orotate (AUC = 0.50 ± 0.21). In the case of pathogens, MIC values were significantly lower for ascorbate (4.50 ± 3.69 μg/ml) than for comenat (6.31 ± 5.58 μg/ml), nicotinate (10.98 ± 9.37 μg/ml), oxybutyrate (7.45 ± 4.73 μg/ml), aspartate (6.37 ± 4.71 μg/ml) and lithium orotate (7.27 ± 5.81 μg/ml). Thus, lithium ascorbate is more effective in supporting commensal bacteria of a positive microbiota than the other three lithium salts and is characterized by certain antibacterial properties against pathogenic bacteria. At the same time, the ubiquitous lithium carbonate, which does not contain any fragments of organic molecules, will not have any positive effect on the state of the microbiota.
- Published
- 2022
- Full Text
- View/download PDF
30. Features of diet therapy for H. pylori associated diseases of the gastrointestinal tract
- Author
-
T. L. Pilat, O. N. Minushkin, L. B. Lazebnik, I. V. Zverkov, Yu. G. Kuznetsova, and R. A. Khanferyan
- Subjects
General Medicine - Abstract
This review of the literature is devoted to the importance of nutritional support in the treatment and prevention of diseases of the gastrointestinal tract associated with Helicobacter pylori. Modern data on the biological properties of H. pylori and the mechanisms of colonization of the microorganism in the gastrointestinal mucosa are presented. Information is provided on the virulence factors and factors that promote adhesion, depolymerization and dissolution of protective mucus, damage and circulatory disorders of the gastrointestinal mucosa, secreted by H. pylori (lipopolysaccharides and proteins of the outer shell of the bacterium, enzymes – mucinase, protease, phospholipase, urease, VacA cytotoxin). The article pays special attention to the issues of diet therapy, the role of various foods and their components in the dietary correction of disorders in gastrointestinal diseases associated with H. pylori. The causes of nutritional disorders in patients with gastrointestinal diseases are described and a detailed description of food products and their biologically active components with anti-Helicobacter activity is given. A special section is devoted to the use and effectiveness of specialized dietary products for therapeutic and preventive nutrition of domestic production (LLC “Leovit nutria”) and the features of use in diseases of the gastrointestinal tract mediated by H. pylori. The authors provide information on the composition of dietary products, their anti-inflammatory, antioxidant, immunotropic and other activities that underlie clinical efficacy. The article provides detailed recommendations on the use of specialized dietary foods for this pathology.
- Published
- 2022
- Full Text
- View/download PDF
31. Report on the 1st stage of the XXV Anniversary Congress of the Scientific Society of Gastroenterologists of Russia (NOGR) and the 24th International Slavic-Baltic Scientific Forum 'St. Petersburg - Gastro-2022 ON-LINE'
- Author
-
L. B. Lazebnik and S. I. Sitkin
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
- Full Text
- View/download PDF
32. Report on the work of the Gastroenterological Scientific Society of Russia (GSSR) for 2021
- Author
-
L. B. Lazebnik and S. I. Sitkin
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
- Full Text
- View/download PDF
33. Russian Consensus on 'Hyperammonemia in Adults': The 2021 Version (in English)
- Author
-
L. B. Lazebnik, E. V. Golovanova, S. A. Alekseenko, A. O. Bueverov, E. Y. Plotnikova, A. I. Dolgushina, L. Y. Ilchenko, T. V. Ermolova, L. V. Tarasova, E. D. Lee, Y. V. Tsyganova, V. A. Akhmedov, E. A. Ageeva, V. M. Losev, I. N. Kupriyanova, S. N. Serikova, N. V. Korochanskaya, L. G. Vologzhanina, Y. S. Zimmerman, E. I. Sas, S. V. Zhuravel, S. V. Okovitiy, M. F. Osipenko, V. G. Radchenko, G. S. Soldatova, S. I. Sitkin, P. V. Seliverstov, G. V. Shavkuta, E. N. Butova, and S. A. Kozhevnikova
- Subjects
Hepatology ,Gastroenterology - Abstract
Hyperammonemia is an acute or chronic intoxication with ammonia and ammonium associated with elevated ammonia levels in serum due to either its increased production and/or decreased detoxification. Hyperammonemia can result from a variety of causes and clinically presents with unspecific signs and symptoms, including asthenia, encephalopathy, liver steatosis or fibrosis, and sarcopenia. With impaired liver function, hyperammonemia most frequently manifests in (micro)encephalopathy. Thus in case of unexpect change in mental status hyperammonemia must be excluded as fast as possible. An express method of photometric assay is informative enough to determine the ammonia levels. The following hyperammonemia classification is proposed: a) by ammonia levels (normal level: ≤ 60 μmol/L; mild (Grade 1): ≤ 100 μmol/L; moderate (Grade 2): ≤ 200 μmol/L; and severe (Grade 3): > 200 μmol/L); b) by etiopathogenesis (hereditary (congenital), functional (physiological), acquired (hepatic, extrahepatic, mixed)); c) by clinical presentation (transient, recurrent or persistent, constant (stable, without treatment), covert). Treatment for hyperammonemia is aimed at treating the primary disease and includes a diet that is restricted in animal protein but contains sufficient vegetable protein, limited physical activities, and use of intestinal non-absorbable antibiotics (rifaximin- alpha) as well as pre- and probiotics. L-ornithine- L-aspartate (LOLA) is a baseline therapeutic product administered in a number of scenarios to correct the level of hyperammonemia.
- Published
- 2022
- Full Text
- View/download PDF
34. NAFLD Associated Comorbidity
- Author
-
L. B. Lazebnik and S. V. Turkina
- Subjects
Hepatology ,Gastroenterology ,nutritional and metabolic diseases - Abstract
Non-alcoholic fatty liver disease (NAFLD) is considered not only as a disease with poor hepatic prognosis. The problem has acquired a multidisciplinary problem. The variety of concomitant diseases and pathological conditions are united by common pathophysiological mechanisms.This review summarizes and presents the data available in the modern literature on the association of NAFLD with cardiovascular diseases, type 2 diabetes mellitus, polycystic ovary syndrome, chronic kidney disease, etc. The role of the liver in the homeostasis of the organism and the pathogenetic mechanisms of the formation of NAFLD-associated comorbidity are discussed.
- Published
- 2021
- Full Text
- View/download PDF
35. Nonalcoholic liver disease: review with a focus on risks of progression
- Author
-
D. A. Teplyuk, S. M. Sorokoletov, M. Ch. Semenistaya, L. B. Lazebnik, and Ch S Pavlov
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Fatty liver ,Gastroenterology ,medicine.disease ,Therapeutic approach ,Liver disease ,Pharmacotherapy ,Nonalcoholic fatty liver disease ,medicine ,Etiology ,Steatohepatitis ,Intensive care medicine ,business ,Diffi cult - Abstract
Nonalcoholic fatty liver disease (NAFLD) is a disease which etiology is related to various metabolic, ethnic, genetic and even ecologic factors. Complexity of etiology and multiply pathogenesis ways, leading eventually to the lipid droplets appearance in hepatocytes, infl ammation process and parenchyma fi brosis in liver, and also frequent cardiometabolic comorbidities, together make diffi cult risks stratifi cation and prognosis evaluation in NAFLD patients. Another matter is a question of NAFLD therapy, since unifi ed pharmacotherapy approaches are not yet adopted worldwide, and lifestyle modifi cation being accepted as an eff ective therapeutic approach, is not followed by patients in real world setting. Current review is dedicated to the consideration of NAFLD diagnostics, its risk of progression and existing therapeutical capabilities.
- Published
- 2021
- Full Text
- View/download PDF
36. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia
- Author
-
O. A. Mekhtieva, L. B. Lazebnik, А. I. Khavkin, E. A. Lyalyukova, B. A. Volel, D. S. Petelin, V I Simanenkov, S. I. Sitkin, N. V. Korochanskaya, Z. V. Metsaeva, M. V. Mokshina, S. V. Cheremushkin, M. V. Chernogorova, S. N. Mekhtiev, and E. V. Golovanova
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,Functional heartburn ,BILIARY PAIN ,Overlap syndrome ,medicine.disease ,Functional disorder ,Internal medicine ,medicine ,SMALL BOWEL BACTERIAL OVERGROWTH ,business ,Scientific society ,Irritable bowel syndrome - Published
- 2021
- Full Text
- View/download PDF
37. Change in concentration of ammonia and other biochemical indicators in patients with new coronaviral infection
- Author
-
E. A. Komarova, E. I. Busalaeva, A. V. Oreshnikov, E. V. Barsukova, S. F. Oreshnikova, L. V. Tarasova, Yu V. Tsyganova, and L. B. Lazebnik
- Subjects
medicine.medical_specialty ,Hepatology ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Fatty liver ,Gastroenterology ,Inflammation ,Hyperammonemia ,Disease ,medicine.disease ,medicine.disease_cause ,Peripheral blood ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,030211 gastroenterology & hepatology ,In patient ,medicine.symptom ,business ,Coronavirus - Abstract
The article demonstrates the results of a study to study the comparative assessment of the concentration of ammonia in the peripheral blood of patients with a viral infection of COVID-19 against the background of previously existing hepatic pathology and without it. There was a correlation between peripheral blood hyperammonemia and an increase in the concentration of markers of acute inflammation. The relationship between a high degree of hyperammonemia and a severe course / death as a result of the development of a new coronavirus infection in the studied patients was traced. The role of the initial chronic hepatic pathology (including non-alcoholic fatty liver disease) as a factor in the unfavorable course of the new coronavirus infection is highlighted.
- Published
- 2021
- Full Text
- View/download PDF
38. In memory of a colleague. Leonid I. Efremov (10/15/1940-11/02/2022)
- Author
-
L. B. Lazebnik
- Subjects
Hepatology ,Gastroenterology - Published
- 2023
- Full Text
- View/download PDF
39. Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (2nd edition)
- Author
-
O. A. Gromova, A. K. Ratnikova, Y. A. Kravchuk, Tkachenko Ei, K. V. Kozlov, D. I. Abdulganieva, V. B. Grinevich, V. I. Ped, Eremina, E. Yu, Sarsenbaeva, A. S., V. V. A. Ratnikov, E V Golovanova, S. P. Salikova, P. A. Makarchuk, L. B. Lazebnik, I. V. Gubonina, E. A. Belousova, E. I. Sas, S. I. Sitkin, and L. V. Tarasova
- Subjects
0301 basic medicine ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Hepatology ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Gastroenterology ,Clinical Practice ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Political science ,Internal medicine ,Pandemic ,medicine ,030211 gastroenterology & hepatology ,Slavic languages ,Scientific society - Abstract
The presented clinical practice guidelines of the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The guidelines were approved by the XXIII Congress of the GSSR and the 22nd International Slavonic-Baltic Scientifi c Forum “St. Petersburg - Gastro-2020 ON-LINE” (St. Petersburg, June 11, 2020). The presented clinical practice guidelines of the Russian Scientific Medical Society of Internal Medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The recommendations were approved at the XV National Congress of Internal Medicine, XXIII Congress of NOGR on the basis of the 1st edition, adopted at the 22nd International Slavic- Baltic Scientific Forum “St. Petersburg - Gastro-2020 ON-LINE”.
- Published
- 2021
- Full Text
- View/download PDF
40. Review of the monograph Yu. L. Fedorchenko, N. V. Korneeva, A. N. Evseeva and M. V. Martynyuk 'Diseases of the upper gastrointestinal tract in diabetic patients'
- Author
-
L. B. Lazebnik
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
- Full Text
- View/download PDF
41. Management of treatment on the basis of adherence
- Author
-
I.A. Vasil'eva, I. V. Poddubnaya, Iu.P. Skirdenko, E. V. Roitman, L. B. Lazebnik, Dentistry, Moscow, Russia, Rehabilitology, Moscow, Russia, A. Martynov, O. I. Vinogradov, A.V. Ershov, Nikolai Nikolaev, and V. N. Anisimov
- Subjects
medicine.medical_specialty ,Basis (linear algebra) ,business.industry ,Medicine ,business ,Intensive care medicine - Published
- 2020
- Full Text
- View/download PDF
42. Management of adherence-based treatment. Consensus document – clinical guidelines. English version
- Author
-
Nikolai Nikolaev, Anatolii Martynov, Yulia Skirdenko, V. N. Anisimov, I. A. Vasilieva, O. I. Vinogradov, L. B. Lazebnik, and I. V. Poddubnaya
- Subjects
Medical education ,English version ,General Medicine ,Psychology - Published
- 2021
- Full Text
- View/download PDF
43. Treatment management based on adherence: patient recommendation algorithms. Cross-disciplinary guidelines
- Author
-
E. V. Roitman, O. I. Vinogradov, F. T. Ageev, I. A. Vasilieva, Yulia Skirdenko, I. V. Poddubnaya, A I Martynov, Nikolai Nikolaev, V. N. Anisimov, and L. B. Lazebnik
- Subjects
Treatment management ,medicine.medical_specialty ,business.industry ,Cross disciplinary ,Medicine ,Medical physics ,General Medicine ,business - Published
- 2020
- Full Text
- View/download PDF
44. RECOMMENDATIONS ON MANAGEMENT OF PRIMARY CARE PATIENTS WITH SYMPTOMS OF DYSPEPSIA
- Author
-
I. V Putintseva, S. M. Kolesnikova, E. I. Kashkina, I. G. Pakhomova, M. A. Umetov, V. A. Nevzorova, M. A. Pleshkova, E. S. Vyuchnova, R. G. Saifutdinov, E. A. Tomina, L. S. Grebeneva, O. V. Yacob, G. B. Selivanova, S. Yu. Serebrova, V. N. Drozdov, D. S. Bordin, I. G. Bakulin, J. A. Khabarova, S. A. Alexeenko, I. V. Kozlova, A. A. Yakovlev, E. V. Luzina, I. B. Ponomareva, M. M. Petrova, O. Yu. Pozdnyakova, S. V. Turkina, O. B. Arkin, E. N. Kareva, E. N. Otteva, S. R. Abdulkhakov, E. A. Kizova, R. A. Abdulkhakov, N. Yu. Alekseev, D. L. Nepomnyashchikh, N. N. Vasilyev, Ltd 'Zdorovje', N. N. Dekhnich, N. V. Kulakova, Kazan, O. G. Kompaniets, E. D. Lee, I. A. Podyapolskaya, E. V. Golovanova, N. V. Korochanskaya, Gbuz But they Nocb N. A. Semashko, Z. F. Gimaeva, V. A. Akhmedov, E. V. Kazakova, Fgbou Vo RyazGMU, S. S. Vyalov, L. I. Dyatchina, I. N. Yurchenko, M. V. Mokshina, N. V. Voronina, R. G. Bashaeva, N. S. Shatokhina, N. N. Nikolaeva, G. A. Batischeva, N. A. Konyshko, I. L. Petrunko, M. G Shpuntov, A. A. Zhilina, S. G. Peshekhonov, L. G. Smolkova, A. S. Sarsenbaeva, N. M. Kozlova, I. I. Khamnagadaev, E. N. Chernysheva, I. I. Belova, T. V. Dmitrieva, O. V. Ryzhkova, M.A. Vise-Khripunova, A. K. Starodubtsev, G. N. Tarasova, K. B. Mozes, M. S. Turchina, L. B. Lazebnik, L. V. Fedorova, O. V. Fedorishina, A. A. Stepchenko, E. D. Lapina, Gbu Rs, Gauz 'Municipal Polyclinic No ', T. V. Vlasova, I. G. Khripunova, A. G. Kononova, A. A. Samsonov, T. N. Yankovaya, D. O. Kurguzova, O. V. Mironchev, E. N. Kolodey, N. V. Bakulina, I. N. Grigorieva, O. V. Khlynova, T. N. Sviridova, Т. V Zhestkova, V. V. Tsukanov, E. A. Lyalukova, I. V. Dolgalev, E. S. Panina, O. V. Stefanyuk, M. A. Shevyakov, O. A. Mubarakshina, and E. V. Onuchina
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,medicine ,Primary care ,Intensive care medicine ,business - Published
- 2018
- Full Text
- View/download PDF
45. RECOMMENDATIONS FOR THE PREVENTION AND TREATMENT OF ESOPHAGO- GASTRO- ENTERO-COLOPATHY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS 'NSAID'
- Author
-
Dmitry S. Bordin, M. A. Shevyakov, A. S. Sarsenbaeva, A. V. Okhlobystin, E. S Vyupkina, V. A. Kokorin, S A Alekseenko, Moscow Clinical, Zh.G. Simonova, E. V. Onuchina, E. I. Kashkina, Tkachenko Ei, Scientifi c, I. V. Putintseva, O. Yu. Pozdnyakova, N V Bakulina, T. N. Yankovaya, E. D. Lee, A Yu Baranovsky, V. D. Pasechnikov, Stanislav Sitkin, O. V. Mironchev, Yu.A. Khabarova, E. I. Miguskina, S. V. Turkina, G. V. Belova, A. A. Yakovlev, E. V. Golovanova, I. G. Pakhomova, V I Simanenkov, E. D. Lapina, L. B. Lazebnik, T. N. Sviridova, I. Z. Gaidukova, E. P. Yakovenko, Z. F. Gimaeva, and I. V. Kozlova
- Subjects
medicine.medical_specialty ,chemistry.chemical_compound ,Nonsteroidal ,Hepatology ,chemistry ,business.industry ,Gastro ,Internal medicine ,Gastroenterology ,Medicine ,business - Published
- 2018
- Full Text
- View/download PDF
46. DIAGNOSTIC EVALUATION OF PATIENT WITH DYSPEPSIA SYNDROME AND HEARTBURN BY GP AND PRIMARY CARE PHYSICIAN: NEED OF A NEW & SIMPLE QUESTIONNAIRE
- Author
-
Kareva En, S. A. Alexeenko, А. А. Samsonov, V. V. Tsukanov, L. B. Lazebnik, S. Yu. Serebrova, and Е. А. Lyalyukova
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,medicine ,Primary care physician ,Heartburn ,Diagnostic evaluation ,medicine.symptom ,Intensive care medicine ,business ,Simple (philosophy) - Published
- 2018
- Full Text
- View/download PDF
47. Report on the 3rd stage of the 23rd Congress of the Scientific Society of Gastroenterologists of Russia
- Author
-
L. B. Lazebnik
- Subjects
Economic growth ,Hepatology ,Stage (stratigraphy) ,Political science ,Gastroenterology ,Scientific society - Published
- 2020
- Full Text
- View/download PDF
48. Report on the work of the 2nd stage of the XXIII Congress of the Scientifi c Society of Gastroenterologists of Russia (NOGR) (St. Petersburg, November 13–14, 2020)
- Author
-
E A Kornienko, S. I. Sitkin, and L. B. Lazebnik
- Subjects
History ,Hepatology ,Work (electrical) ,Stage (stratigraphy) ,Gastroenterology ,Library science ,St petersburg - Published
- 2020
- Full Text
- View/download PDF
49. [HEREDITARY HEMOCHROMATOSIS (clinical observations)]
- Author
-
E V, Golovanov, L B, Lazebnik, V Yu, Konev, and N, Shaposhnikov
- Subjects
Aged, 80 and over ,Male ,Humans ,Hemochromatosis ,Aged - Abstract
The article presents two clinical observations of patients with different course genetically verified primary hemochromatosis.
- Published
- 2018
50. A REVIEW OF INTERNATIONAL AND NATIONAL CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT-OF NONALCOHOLIC FATTY LIVER DISEASE
- Author
-
E V, Golovanova and L B, Lazebnik
- Subjects
Non-alcoholic Fatty Liver Disease ,Practice Guidelines as Topic ,Humans - Abstract
The review presents comparative characteristics of domestic and foreign clinical guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.